TNGX Tango Therapeutics Corp Company Short-Term Debt

Tango Therapeutics, Inc. - graphic logo of issuer TNGX

Tango Therapeutics (TNGX) is developing immunotherapy-based cancer treatments while outsourcing all drug production to third-party contractors, leaving the company vulnerable amid fierce competition for clinical trial participants. This chart of the market value reflects the 0.00 indicator. Meanwhile, the business is protected by US law and remains insulated from the impact of international conflicts or trade restrictions.

TNGX tangotx.com Short-Term Debt (07/04/2022 - 10/30/2026)

Analytical breakdowns and data insights for company Tango Therapeutics Corp (TNGX)

- current quotes and average value forecast:
Price Chart Tango Therapeutics, Inc.|TNGX - Average Forecast Price
- market capitalization data:
Market Value Tango Therapeutics, Inc.|TNGX - Total Company Value
- shareholders' equity book value data:
Net Assets per Single Share Tango Therapeutics|TNGX - Total Stockholders' Equity|Market Capitalization to Book Value Ratio tangotx.com|TNGX - Company Balance Sheet Assets
- company total debt and liquidity indicators:
Total Debt to Equity Ratio Tango Therapeutics|TNGX - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Tango Therapeutics|TNGX - Aggregate Debt Obligations|Debts to Book Capitalization Tango Therapeutics, Inc.|TNGX - Long-Term Debt Volume|Company Short-Term Debt Tango Therapeutics|Quick Liquidity tangotx.com
- earnings and multiples data:
TNGX - Net Income
General company analysis:Tango Therapeutics, Inc. (TNGX)
Flagship merchandise of tangotx.com

Short-term debts reflect the total liabilities requiring repayment within one year. By analyzing debt with a maturity of up to one year, an investor assesses the company's liquidity and default risk. The stability of this metric confirms the effectiveness of working capital management. For Tango Therapeutics (TNGX), loan control is critical due to the capital intensity of cancer immunotherapy development. High research costs make the company dependent on the availability of external financing.

Competitors of Tango Therapeutics

IBRX - Company Short-Term Debt|Short-Term Debt Immunocore Holdings|Janux Pharma (JANX) - Company Short-Term Debt|RCUS (Arcus Corp) - Company Short-Term Debt|Company Short-Term Debt Zymeworks Inc.|Short-Term Debt iovance.com IOVA|Company Short-Term Debts IMTX|Xencor Inc (XNCR) - Short-Term Indebtedness|Compass Bio - Company Current Liabilities|Replimune Inc. (REPL) - Short-Term Debt|LYEL: Company Current Liabilities|Company Short-Term Loans and Borrowings IPHA (innate-pharma.com)|PYXS: Company Short-Term Debts|CGEN - Short-Term Debt Volume|Company Short-Term Debt IO Biotech Corp|Company Current Liabilities Sutro Biopharma, Inc (STRO)|Company Short-Term Debt MiNK Therapeutics, Inc. (INKT)|Company Current Liabilities werewolftx.com HOWL|Immix Biopharma - Company Current Liabilities|Company Short-Term Debts alxoncology.com ALXO|CUE - Company Short-Term Debt|PDSB (PDS Biotechnology) - Company Short-Term Indebtedness|sonnetbio.com (SONN) - Company Short-Term Debt|Short-Term Debt MAIABiotech.com (MAIA)|Company Current Liabilities LIMN|LVTX - Short-Term Indebtedness|Company Current Liabilities NXTC (NextCure Corp)|Amount of Current Liabilities LPTX|Company Short-Term Debts INTS (Intensity Therapeutics, Inc.)|Company Short-Term Loans and Borrowings SNSE|Theriva Biologics - Company Short-Term Debts|Short-Term Debt Gritstone bio, Inc.|Kineta Bio (KA) - Company Short-Term Debt|NexImmune Corporation - Company Short-Term Loans and Borrowings|TSBX (Turnstone Biologics Corp) - Company Short-Term Debts|Company Short-Term Debts vaccinex.com|Company Short-Term Debt Harpoon Therapeutics, Inc. (HARP)